Apellis Pharmaceuticals has been slowly rebounding from an unjustified safety scare related to its approved treatment for a common type of vision loss. Now, a competing medicine from Astellas, also recently approved, may have stumbled, which could further boost Apellis’ business outlook — and its stock price.
In a statement released Monday night, Astellas announced the “positive” outcome of an important follow-up analysis meant to demonstrate the two-year efficacy of its drug, called Izervay, in people with geographic atrophy.
I’m skeptical. The bulk of Astellas’ announcement reads like a spin job. And when I asked the company for clarifying information, it waited an entire day before responding.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.